Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?

Movement Disorders

Volumn 16, Issue 5, 2001, Pages 804-806

  Stoessl, Jon A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; AMPHETAMINE; ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOCHEMICAL MARKER; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER; IODINE 123; RACLOPRIDE; TECHNETIUM 99M;

BINDING AFFINITY; CELL LOSS; CELL TRANSPORT; CORRELATION ANALYSIS; DECARBOXYLATION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOWN REGULATION; DRUG BINDING; DRUG EFFECT; EDITORIAL; GENETIC DISORDER; HUMAN; IMAGING SYSTEM; ISOTOPE LABELING; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; FLUORINE RADIOISOTOPES; HUMANS; NEURAL PATHWAYS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0035470413     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1192     Document Type: Editorial

References (16)

1. Yee RE, Irwin I, Milonas C, Stout DB, Huang S-C, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki DM, Farahani KF, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 2001;16:838-848.
2. Yee RE, Huang S-C, Stout DB, Irwin I, Shoghi-Jadid K, Togaski DM, Delanney LE, Langston JW, Satyamurthy N, Farahani KF, et al. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations. J Neurochem 2000;74:1147-1157.
3. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
4. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, Ruth TJ, Calne DB. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34:331-338.
5. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
6. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542.
7. Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhlef A, Margouleff C, Mandel F, Eidelberg D. Combined FDOPA and 30MFD PET studies in Parkinson's disease. J Nucl Med 1996;37209-37216.
8. Vingerhoets FJG, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine 18-6-fluoro-L-Dopa PET in Parkinson's disease. J Nucl Med 1996;37:421-426.
9. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
10. Vanderborght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
11. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16:3507-3510.
12. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, et al. In vivo PET evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
13. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999;21137-21140.
14. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
15. 123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46:231-237.
16. Mozley PD, Schneider JS, Acton PD, Plossl K, Stern MB, Siderowf A, Leopold NA, Li PY, Alavi A, Kong HF. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000; 41:584-589.